Serum CYR61 as a potential biomarker to improve breast cancer diagnostics.

To investigate the role of serum CYR61 as a biomarker for the diagnosis of breast cancer and to analyze the association between serum CYR61 levels and the clinicopathological features in breast cancer patients. Serum CYR61 was measured in breast cancer patients and healthy controls by ELISA. The serum levels of CYR61 in breast cancer patients were higher than those in healthy controls. The area under the receiver operating characteristic curve for CYR61 was higher than that for carcinoembryonic antigen and carbohydrate antigen 15-3. The increased CYR61 levels were correlated with menopausal status and Ki67 expression. Serum CYR61 might be a novel biomarker to assist the diagnosis and clinicopathological status assessment of breast cancer.